Salute e Benessere

LILYSILK Continues Partnership with National Breast Cancer Foundation for Breast…

In March 2024, LILYSILK introduced the Caring Collection in collaboration with NBCF. The collection features silk items such as Hope's Comfort Pillowcase, Eternal Hope Scrunchie, Hopeful Dreams Sleep Eye Mask, and The Hope's Embrace Sleep Set. Each item reflects LILYSILK's dedication to comfort and support for breast cancer patients. Packaged with a pink ribbon-themed seal and messages of gratitude, the collection symbolizes the company's commitment to the fight against breast cancer and its…
PR Newswire
29/10/2024

QuantalX Introduces a Breakthrough in the Diagnosis and Classification of…

Delphi-MD's cutting-edge, direct electrophysiological imaging technology provides real-time insights into brain network function. The system identifies specific physiological changes in brain networks, particularly in the occipital networks, occurring in the early stages of Parkinson's disease. Delphi-MD enables the identification of patients with rapid disease progression, allowing for early intervention and personalized treatment, marking a first in neurological clinical care and potentially…
PR Newswire
29/10/2024

415 Capital Announces €150 Million Second Fund and Key Appointments to…

The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon. The fund has already made investments in two clinical-stage cardiovascular companies, with additional transactions expected to be announced soon. "We are incredibly grateful for the trust our limited partners continue to place in us. Their support highlights the significant clinical impact and value of our portfolio,"said Frederik…
PR Newswire
29/10/2024

Contract Win

DXS INTERNATIONAL PLC(AQSE: DXSP)ExpectCare First Commercial Contract The Board of DXS International plc (“the Company” or “DXSP”), the AQSE Growth Market quoted healthcare information and digital clinical decision support systems provider, is pleased to announce its first NHS commercial contract for its leading-edge AI ExpertCare Clinical Decision Support (CDS) solution. This unique digital solution “automates” the gathering of all “relevant” patient and NICE treatment...
Nasdaq GlobeNewswire
29/10/2024

Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer

BiogenInc. (Nasdaq: BIIB) has appointed Daniel Quirk, M.D., M.P.H., M.B.A. as Chief Medical Officer and Head of Medical Affairs, effective October 28, 2024. Dr. Quirk will report to Priya Singhal, M.D., M.P.H., Head of Development at Biogen.“At Biogen, scientific and medical leadership is the foundation for everything we do, and this is why we believe Dan will be a perfect fit to lead our Medical Affairs organization going forward,” said Priya Singhal, M.D., M.P.H., Head of Development at...
Nasdaq GlobeNewswire
29/10/2024

Ardena Expands Bioanalytical Services in Europe

The new 3,000+ sqft lab in Oss, expected to be operational by Q1 2025, will provide advanced analytical testing services for both small and large molecules, employing LC-MS/MS and fluorometric detection assays, along with ELISA-based Gyrolab automated technology platform. Meanwhile, Ardena's investments in Assen focus on expanding its capabilities in immunochemistry, flow cytometry, and qPCR platforms, increasing its LC-MS/MS capacity, and adding new Hamilton automated systems to enhance...
Nasdaq GlobeNewswire
29/10/2024

Updated version of the company's articles of association

The updated Articles of Association of MAXIMA GRUPĖ, UAB are announced. Contact person:Lukas RadžiūnasHead of Corporate Relations and Communications+370 666 21 [email protected] Attachment MXGR_Istatai_registruoti 2024-10-24
Nasdaq GlobeNewswire
29/10/2024

GemVax Announces Topline Results from Phase 2a Progressive Supranuclear Palsy…

PSP is a degenerative disease that, like Parkinson's disease, causes symptoms such as gait disturbances, early falls, vertical gaze palsy, rigidity, tremors, and cognitive decline, but it progresses faster and currently has no fundamental treatment. PSP is classified into several types, including PSP-Richardson's syndrome ("PSP-RS") and PSP-parkinsonism ("PSP-P"). Compared to other types of PSP, the PSP-RS type shows a greater accumulation of tau protein and affects larger…
PR Newswire
29/10/2024

Zymeworks Announces Participation in Upcoming Investor Conferences

UBS Global Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 12 in Rancho Palos Verdes, CA.Stifel 2024 Healthcare Conference: Zymeworks' management will participate in one-on-one meetings and a fireside chat on November 19 at 4:10 pm Eastern Time (ET) in New York, NY.Jefferies London Healthcare Conference: Zymeworks' management will participate in one-on-one meetings on November 20-21 and a fireside chat on November 20 at 2:30 pm Greenwich...
Nasdaq GlobeNewswire
29/10/2024

Discovery of cancer risk associations for six novel genes

In this study, the scientists analysed three large genetic datasets from individuals of European descent, including 130,991 cancer patients and 733,486 controls. Through a gene-based burden association analysis across 22 different cancer types, they found four novel genes associated with a risk of developing cancer; the pro-apoptotic BIK for prostate cancer, the autophagy involved ATG12 for colorectal cancer, TG for thyroid cancer, and CMTR2 for both lung cancer and cutaneous melanoma. The…
PR Newswire
29/10/2024

Orion Group Interim Report January–September 2024

ORION CORPORATIONINTERIM REPORT 1–9/202429 OCTOBER 2024 at 12:00 EETOrion Group Interim Report January–September 2024Net sales totalled EUR 1,108.0 (January–September 2023: 868.5) million Operating profit was EUR 323.8 (182.0) millionBasic earnings per share were EUR 1.83 (1.01)Cash flow from operating activities per share was EUR 1.46 (0.50)The outlook for 2024 was upgraded during the reporting period on 11 September 2024: Net sales are estimated to be EUR 1,470 million to...
Nasdaq GlobeNewswire
29/10/2024

Regional and Global Experts Convene in Accra, Ghana to Update Cancer Treatment…

The NCCN Harmonized Guidelines™ for Sub-Saharan Africa are free resources for optimizing and standardizing cancer care across the region. They are available at NCCN.org/harmonized or via the Virtual Library of NCCN Guidelines® App. The NCCN Harmonized Guidelines™ for Sub-Saharan Africa are free resources for optimizing and standardizing cancer care across the region. They are available atNCCN.org/harmonizedor via theVirtual Library of NCCN Guidelines ®App. "The Sub-Saharan Africa...
PR Newswire
29/10/2024

MGI Tech and OncoDNA join forces to offer laboratories a streamlined NGS…

Previously limited to one sequencing technology/platform provider, the OncoDEEP® Kit's analysis process now also provides exceptional results and clinical insights, supporting laboratories in performing solid tumor Comprehensive Genomic Profiling using MGI sequencers which utilize the cutting-edge DNBSEQ™ technology. Previously limited to one sequencing technology/platform provider, the OncoDEEP ®Kit's analysis process now also provides exceptional results and clinical insights, supporting...
PR Newswire
29/10/2024

First Children Vaccinated in New Clinical Study Seeking to Expand the Indication…

Clinical study in children 2-11 years of age follows the recent EMA and WHO approvals of the MVA-BN mpox vaccine for adolescents 12-17 of age.COPENHAGEN, Denmark, October 29, 2024– Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of a clinical study of the MVA-BN ®mpox/smallpox vaccine in children 2 to 11 years of age.The first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to...
Nasdaq GlobeNewswire
29/10/2024

Idorsia announces financial results for the first nine months of 2024

Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – October 29, 2024 Idorsia Ltd (SIX: IDIA) today announced its financial results for the first nine months of 2024. Highlights Net revenue9M 2024 at CHF 53 million. US GAAP operating loss9M 2024 of CHF 154 million andNon-GAAP operating lossof CHF 248 million. Improved Guidancefor 2024, driven by diligent cost control. QUVIVIQ™(daridorexant) total net sales of CHF 39 million in 9M 2024.Commercial...
Nasdaq GlobeNewswire
29/10/2024

Novartis continues strong momentum in Q3 with 10% sales growth, 20% core…

Ad hoc announcement pursuant to Art. 53 LR Q3 net sales grew +10% (cc 1, +9% USD) with core operating income up +20% (cc, +17% USD)Sales growth driven by continued strong performance fromEntresto(+26% cc),Cosentyx(+28% cc),Kisqali(+43% cc),Kesimpta(+28% cc),Pluvicto(+50% cc) andLeqvio(+119% cc)Core operating income margin 40.1%, +340 basis points (cc), mainly driven by higher net sales Q3 operating income grew +123% (cc, +106% USD); net income…
Nasdaq GlobeNewswire
29/10/2024

The world's first 100% “fiber-to-fiber” biorecycled clothing unveiled by…

For the first time, a piece of clothing is made entirely from textile waste – no bottles, no packaging, no virgin plastic. 100% biorecycled fibers.By developing and industrializing CARBIOS' enzymatic depolymerization technology to achieve 100% “fiber-to-fiber” recycling, the consortium collectively advances the textile industry's shift towards a circular economy Clermont-Ferrand (France), 29 October 2024 (06.45am CET). CARBIOS,(Euronext Growth Paris : ALCRB), a pioneer in the...
Nasdaq GlobeNewswire
29/10/2024

Treg Cell-based Therapies Clinical Trial Pipeline Appears Robust With 51+ Key…

Key Takeaways from the Treg Cell-based Therapies Pipeline Report Key Takeaways from the Treg Cell-based Therapies Pipeline Report Request a sample and discover the recent advances in Treg cell-based therapies @ Treg Cell-based Therapies Pipeline Outlook The Treg cell-based therapies pipeline report provides detailed profiles of pipeline assets, a comparative analysis of clinical and non-clinical stage Treg cell-based therapies, inactive and dormant assets, a comprehensive assessment...
PR Newswire
28/10/2024

Emboline, Inc. Files Patent Infringement Suit Against AorticLab s.r.l. Regarding…

The Emboliner is the first device designed to provide complete brain and body protection from ischemic events such as stroke caused by embolic debris released into the bloodstream during transcatheter heart procedures. While transcatheter valve technology and techniques have continued to be refined over the past two decades since the introduction of TAVR, suffering a major debilitating stroke remains a real and persistent threat, and is often cited by patients as being feared more than death…
PR Newswire
28/10/2024

Excipients in Pharmaceuticals: Navigating the Global Market Landscape Through…

This report offers a detailed analysis of the market for pharmaceutical excipients, focusing on the competitive landscape and the revenues and product portfolio of leading companies. It examines trends, challenges, and opportunities, along with market projections through 2029. The report segments the market by excipient types—organic, inorganic, and USP water—as well as specific categories such as carbohydrates (cellulose, sugars, starch), and calcium salts. It also evaluates the three dosage…
PR Newswire
28/10/2024

AB Science receives notice of allowance for European patent covering masitinib…

PRESS RELEASE AB SCIENCE RECEIVES NOTICE OF ALLOWANCE FOR EUROPEAN PATENT COVERING MASITINIB UNTIL 2040 IN THE TREATMENT OF SICKLE CELL DISEASE THIS DECISION FURTHER STRENGTHENS MASITINIB'S INTELLECTUAL PROPERTY ADDING ONE MORE INDICATION WITH LONG TERM PROTECTIONMASITINIB IS IN PHASE 2 IN SICKLE CELL DISEASEParis, October 28, 2024, 5.45pm CETAB Science SA(Euronext - FR0010557264 - AB) today announced that the European Patent Office has issued a Notice of Allowance for a...
Nasdaq GlobeNewswire
28/10/2024

ONWARD® Medical Publishes Closing of Bookbuild Offering

THIS PRESS RELEASE CONTAINS INSIDE INFORMATION WITHIN THE MEANING OF ARTICLE (7)(1) OF THE EUROPEAN MARKET ABUSE REGULATION (596/2014)EINDHOVEN, the Netherlands, Oct.28, 2024(GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD) (the “Company” or “ONWARD Medical”), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), announces today the closing of its previously...
Nasdaq GlobeNewswire
28/10/2024

Gastrointestinal Drugs Market Size to Reach $106.30 Billion By 2031 | CAGR 7.5%…

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/gastrointestinal-drugs-market Browse Detailed Analysis:https://www.theinsightpartners.com/reports/gastrointestinal-drugs-market Overview of Report Findings Market Growth : 1. Market Growth : The gastrointestinal drugs market is expected to reachUS$ 59.71 billionby 2023 fromUS$ 106.30 billionin 2031; it is anticipated to register a CAGR of 7.5% during the forecast period. Gastrointestinal drugs are...
PR Newswire
28/10/2024

Dental Implants Market Size to Reach $11.28 Billion By 2031 | CAGR 8.3%: The…

Browse Detailed Analysis: https://www.theinsightpartners.com/reports/dental-implants-market Browse Detailed Analysis: https://www.theinsightpartners.com/reports/dental-implants-market Overview of Report Findings Get Sample Pages in your inbox: https://www.theinsightpartners.com/sample/TIPHE100000866/ Market Segmentation Get Sample PDF Copy:https://www.theinsightpartners.com/sample/TIPHE100000866/ Competitive Strategy and Development Headlines on Dental...
PR Newswire
28/10/2024
Altri  Comunicati